Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Marcelo V. Negrão, Haniel A. Araújo, Giuseppe Lamberti, et al.
Cancer Discovery (2023) Vol. 13, Iss. 7, pp. 1556-1571
Open Access | Times Cited: 103

Showing 1-25 of 103 citing articles:

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Matthew Holderfield, Bianca J. Lee, Jingjing Jiang, et al.
Nature (2024) Vol. 629, Iss. 8013, pp. 919-926
Open Access | Times Cited: 90
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Jingjing Jiang, Lingyan Jiang, Benjamin J. Maldonato, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 994-1017
Open Access | Times Cited: 74
Targeting KRAS in cancer
Anupriya Singhal, Bob T. Li, Eileen M. O’Reilly
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 969-983
Closed Access | Times Cited: 67
KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance
Anastasia‐Maria Zavitsanou, Ray Pillai, Hao Yuan, et al.
Cell Reports (2023) Vol. 42, Iss. 11, pp. 113295-113295
Open Access | Times Cited: 46
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Míriam Molina‐Arcas, Julian Downward
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 338-357
Open Access | Times Cited: 46
KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing
Tony Kiat Hon Lim, Ferdinandos Skoulidis, Keith M. Kerr, et al.
Lung Cancer (2023) Vol. 184, pp. 107293-107293
Open Access | Times Cited: 43
Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Suman Mukhopadhyay, Hsin‐Yi Huang, Ziyan Lin, et al.
Cancer Research (2023) Vol. 83, Iss. 24, pp. 4095-4111
Open Access | Times Cited: 42
Non-small-cell lung cancer
Lizza E.L. Hendriks, Jordi Remón, C. Faivre‐Finn, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 37
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
Xinyuan Tong, Ayushi Patel, Eejung Kim, et al.
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 413-428.e7
Open Access | Times Cited: 33
Combinatorial strategies to target RAS-driven cancers
Naiara Perurena, Lisa Situ, Karen Cichowski
Nature reviews. Cancer (2024) Vol. 24, Iss. 5, pp. 316-337
Closed Access | Times Cited: 22
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer
Ray Pillai, Sarah E. LeBoeuf, Yuan Hao, et al.
Science Advances (2024) Vol. 10, Iss. 13
Open Access | Times Cited: 19
KRAS G12C inhibitor combination therapies: current evidence and challenge
Hirotaka Miyashita, Shumei Kato, David S. Hong
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 15
A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer
Daoyan Wei, Liang Wang, Xiangsheng Zuo, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 4, pp. 655-662
Open Access | Times Cited: 35
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors
A. Cole Edwards, Clint A. Stalnecker, Alexis Jean Morales, et al.
Cancer Research (2023) Vol. 83, Iss. 24, pp. 4112-4129
Open Access | Times Cited: 30
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
Alessandro Di Federico, Ilaria Ricciotti, Valentina Favorito, et al.
Current Oncology Reports (2023) Vol. 25, Iss. 9, pp. 1017-1029
Closed Access | Times Cited: 22
Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib
Sophie M. Ernst, Ronald van Marion, Peggy N Atmodimedjo, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 7, pp. 995-1006
Closed Access | Times Cited: 14
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
Marie‐Julie Nokin, Alessia Mira, Enrico Patrucco, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go
Vito Longo, Annamaria Catino, Michele Montrone, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3237-3237
Open Access | Times Cited: 10
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non–Small Cell Lung Cancer
Haniel A. Araújo, Ximo Pechuan-Jorge, Teng Zhou, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2183-2208
Closed Access | Times Cited: 10
Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: A systematic review and meta-analysis
Qian Chen, Weihao Lin, Xiao-xiang Zhou, et al.
Pharmacological Research (2024) Vol. 200, pp. 107060-107060
Open Access | Times Cited: 9
Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance
Venu Thatikonda, Hengyu Lyu, Sabine Jurado, et al.
Nature Cancer (2024) Vol. 5, Iss. 9, pp. 1352-1370
Open Access | Times Cited: 9
Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer
Yu Zhang, Liang Liu, Jinpeng Pei, et al.
Oncogene (2024) Vol. 43, Iss. 9, pp. 668-681
Open Access | Times Cited: 8
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
Yuankai Shi, Jian Fang, Ligang Xing, et al.
Nature Medicine (2025)
Closed Access | Times Cited: 1
Current challenges and practical aspects of molecular pathology for non-small cell lung cancers
Paul Hofman, Sabina Berezowska, Daniel Kazdal, et al.
Virchows Archiv (2023) Vol. 484, Iss. 2, pp. 233-246
Open Access | Times Cited: 20
Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels
Lova Sun, Elizabeth A. Handorf, Yunyun Zhou, et al.
Lung Cancer (2024) Vol. 190, pp. 107510-107510
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top